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The metabolic syndrome, aﬀecting a substantial and increasing percentage of the worldwide population, is comprised of a cluster
of symptoms associated with increased risk of type 2 diabetes, cardiovascular disease, and other chronic conditions. Mind-
body modalities based on Eastern philosophy, such as yoga, tai chi, qigong, and meditation, have become increasingly popular
worldwide. These complementary therapies have many reported beneﬁts for improving symptoms and physiological measures
associatedwiththemetabolicsyndrome.However,clinicaltrialdataconcerningtheeﬀectivenessofthesepracticesonthesyndrome
as a whole have not been evaluated using a systematic and synthesizing approach. A systematic review was conducted to critically
evaluate the data from clinical trials examining the eﬃcacy of mind-body therapies as supportive care modalities for management
of the metabolic syndrome. Three clinical trials addressing the use of mind-body therapies for management of the metabolic
syndrome were identiﬁed. Findings from the studies reviewed support the potential clinical eﬀectiveness of mind-body practices
in improving indices of the metabolic syndrome.
1.Introduction
The last 50 years have seen a dramatic increase in metabolic
disorders, including obesity and type 2 diabetes, with the
number of individuals diagnosed with type 2 diabetes
worldwide expected to surpass 360 million by 2030 [1]. This
prevalence is rising given the epidemic of obesity, which is
fueled, in part, by physical inactivity and unhealthy eating
patterns [2]. The metabolic syndrome, which aﬀects nearly
40% of the US population [3], is a complex condition char-
acterized by multiple, interrelated metabolic abnormalities
linked to insulin resistance [4] and exacerbated by aging
[5]. Core features of the metabolic syndrome are insulin
resistance, glucose intolerance, atherogenic dyslipidemia,
visceral adiposity, and hypertension [6, 7]. The symptom
cluster that deﬁnes the metabolic syndrome has been shown
to contribute to the pathogenesis and progression of type
2 diabetes and its related disorders, cardiovascular disease
(CVD), and other chronic conditions [4, 6–14].
Other abnormalities associated with the metabolic
syndrome and linked to the pathogenesis and progres-
sion of chronic diseases include hypercoagulation, chronic
inﬂammation, endothelial dysfunction, oxidative stress, and
reducedbioavailabilityofinsulin-likegrowthfactor-1[8,15–
17]. Increased sympathetic activity and reduced parasympa-
thetic tone have been implicated in the pathogenesis of the
metabolic syndrome and its related complications [15, 18].
In addition, there is mounting evidence that chronic psycho-
logical stress and negative mood states are strongly associ-
ated, in a bidirectional manner, with insulin resistance, glu-
cose intolerance, central obesity, dyslipidemia, hypertension,
and other components of the metabolic syndrome [19–25].
Likewise, prospective studies have shown that depression,
a common comorbidity in individuals with the metabolic
syndrome, increases subsequent risk for developing type 2
diabetes by two- to threefold [21, 26]. Sleep disturbance,
which also increases with age [27] and has been implicated
in the development of insulin resistance [28], has also been2 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
associated with an increased risk for both type 2 diabetes
[29] and its associated complications, as well as other
chronic conditions [30]. Given the dramatically increasing
prevalence, associated premature mortality, disability, com-
plications, and social and economic costs, management of
the metabolic syndrome is of importance to public health.
Modalities such as yoga, tai chi, qigong, and medita-
tion may represent adjuncts to the conventional care and
management of the metabolic syndrome. Records of these
practices extend back to ancient times in Asia, and many
of these forms, now referred to as mind-body therapies,
currently are practiced throughout the world. Use of mind-
body practices have increased in the US in recent years.
Around 20% of the population engage in some form of
mind-body practice based on data from the 2007 National
Health Interview Survey, with yoga, meditation, and deep
breathing exercises being the most popular [31]. Mind-
body modalities have demonstrated eﬃcacy in improving
individual indices that comprise the symptom cluster that
deﬁnes the metabolic syndrome. A recent comprehensive
review found that yoga improved speciﬁc metabolic risk
factors, including blood pressure, lipoprotein proﬁles, body
mass index (BMI), and insulin sensitivity [32]. Clinical trials
havedemonstratedthebeneﬁtsofyogaindiabetes,hyperten-
sion, dyslipidemia, atherosclerosis, improving blood glucose
[33, 34], the insulin-glucose ratio, glycosylated hemoglobin
[34], and requirements for oral hypoglycemics and insulin
[33]a sw e l la sb o d yw e i g h ta n dc o m p o s i t i o n[ 32].
Growing evidence suggests that tai chi and qigong may
improve indices of glycemic control in people with diabetes
[35]. Qigong has been shown to reduce blood pressure
[36], insulin resistance, glucose intolerance, oxidative stress
[37], and other related indices of CVD risk [35, 36]. While
research is limited, ﬁndings suggest the use of qigong
programs for reducing stress, anxiety, and depression and
improving associated health outcomes, including promotion
of adequate sleep [38]. Randomized, controlled trials (RCTs)
of transcendental meditation, a modality restored from
ancient Vedic tradition in India and taught worldwide since
1957, have demonstrated blood pressure-lowering eﬀects
similar to primary antihypertensive medications [39].
Although the mechanisms underlying the putative physi-
ologic and psychological eﬀects of the practice of mind-body
modalities are not yet well understood, the observed changes
likely occur through a number of pathways. By reducing the
activation and reactivity of the sympathoadrenal system and
the hypothalamic pituitary adrenal (HPA) axis and promot-
ing feelings of well-being, mind-body therapies may alleviate
the eﬀects of stress and foster multiple positive downstream
eﬀects on neuroendocrine status, metabolic function, and
related inﬂammatory responses. Also, by directly activat-
ing the vagus nerve, mind-body practices may enhance
parasympathetic output and thereby shift the autonomic
nervous system balance from primarily sympathetic to
parasympathetic,leadingtopositivechangesincardiac-vagal
function, mood, energy state, and related neuroendocrine,
metabolic, and inﬂammatory responses [40]. The demands
of modern society may be responsible for higher levels of
chronic stress, leading to activation of the neurohormonal
system, speciﬁcally the sympathoadrenal system and HPA
axis that involves catecholamine release, vagal withdrawal,
cortisol secretion, and upregulation of the renin-angiotensin
system. While research remains limited, ﬁndings suggest
that the use of mind-body practices reduces stress, anxiety,
and depression and improves associated health outcomes.
These beneﬁts may be particularly important for people at
risk of or with the metabolic syndrome, who may be more
vulnerable to compromised health-related quality of life,
poor psychosocial health, poor self-care practices, increased
healthcare costs, and adverse outcomes [41].
This systematic review critically evaluates the data exam-
ining the eﬃcacy of mind-body therapies as supportive
care modalities for management of the metabolic syndrome,
focusing on studies of the cluster of symptoms that make
up the metabolic syndrome rather than on those studies that
have investigated only single components.
2. Methods
2.1. Data Sources. Electronic databases (MEDLINE, CIN-
AHL, and PubMed) were searched from the respective
inception dates through November 18, 2010, to locate po-
tentially relevant peer-reviewed articles using logical com-
binations of the following search terms: “mind-body,”
“metabolic syndrome,” “yoga,” “tai chi,” “qigong,” “mindful-
ness,” and “meditation”. Additionally, relevant journals and
the references of all located articles were manually searched
for other potentially relevant studies.
2.2. Study Selections. For the purposes of this systematic
review, mind-body therapies were limited to yoga, tai chi,
qigong, mindfulness-based techniques, and any form of
meditation. Studies that assessed one of the deﬁned mind-
body therapies alone or as an adjuvant to conventional
treatment in human subjects with the metabolic syndrome
were included. Trials were excluded if the study examined
a mind-body modality as part of a complex intervention
(i.e., combining a mind-body therapy with another com-
plementary modality), was aimed at the development of
the methodology of mind-body therapy procedures without
clinical outcomes, reported no data or statistical compar-
isons, assessed healthy subjects, or was limited to only
components of the metabolic syndrome (i.e., hypertension
or insulin sensitivity alone). Abstracts were included, and
hard copies of all documents pertaining to the included
studies were obtained and read in full.
2.3. Data Extraction and Quality Assessment. Two indepen-
dent reviewers validated, extracted, and recorded relevant
study data using predeﬁned criteria. Allocation concealment
was assessed using the Cochrane classiﬁcation, and the
quality of all studies was independently assessed using a
modiﬁcation of the scoring criteria used for a previous
review of a bioﬁeld therapy by the authors [44]. Using this
method, a maximum of ﬁve points was awarded. One point
was given for a description of the trial as a randomized study,
onepointforanappropriatemethodofrandomizationbeing
reported, one point for an appropriate control group, andJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 3
Potentially relevant articles identiﬁed
(N = 692)
Identiﬁed as experimental
studies (n = 6)
Included clinical trials (n = 3)
Articles excluded (n = 686):
• Not related to patients with metabolic syndrome (n = 48)
• Not relevant to complementary therapies (n = 14)
• Non-English language (n = 125)
• Errata (n = 9)
• Case reports (n = 39)
• Review articles not related to metabolic syndrome (n = 204)
• Review articles of metabolic syndrome (n = 69)
• Cell or animal study (n = 78)
• N o tp e e rr e v i e w e d( n = 100)
Studies excluded (n = 3):
• Bijlani et al., 2005 [43]: Comorbidities of study population too
heterogeneous
• V´ azquez-Vandyck et al., 2007 [44]: Intervention not mind-body
• Liu et al., 2010 [41]: Only one group
Figure 1: Diagram of review process and trial selection.
one point for the blinding of the evaluator. Given the nature
of the interventions, blinding of the study participants is not
possible and was not included in the scoring of the trials.
An additional point was awarded for reporting the details
concerning withdrawals and dropouts from the trial. Any
discrepancies in the scoring of the trials were resolved by
discussion between the two reviewers.
3. Results
3.1. Study Description. The searches identiﬁed 692 poten-
tially relevant articles, of which 689 articles were excluded.
This resulted in three trials being included in the paper.
A schematic of the excluded studies as well as the reasons
for exclusion are outlined in Figure 1, with key data from
each study summarized in Table 1. One study was excluded
because the comorbidities of the study population were too
heterogeneous and not limited to the metabolic syndrome
[45]. Another study was excluded because the intervention
did nothaveastrongmind-body componentandwasrelated
moretophysicalactivityalonethantoamind-bodymodality
[46]. An additional study was excluded because it was of a
single-group, quasiexperimental design [41].
3.2. Study Quality. The quality scores of the included RCTs
ranged between 2 and 5 out of possible 5 points. Of the three
included trials, only one adequately described the meth-
ods of randomization and reported suﬃcient information
regarding appropriate allocation concealment and assessor
blinding [39]. Details of study dropouts and withdrawals
were reported in two trials [39, 43].
3.3. Included Studies. Paul-Labrador and colleagues [39]
(modiﬁed score = 5) conducted an RCT of transcen-
dental meditation using a two-group, parallel design in
individuals with coronary heart disease and the metabolic
syndrome. Subjects (N = 103) were randomized to either
a transcendental meditation or a health education program
for 16 weeks. Both the meditation and health education
interventions consisted of the same number and frequency
of group meetings. The transcendental meditation interven-
tion involved a highly standardized, traditional protocol,
while the health education intervention was comprised of
lectures and discussions involving risk factors for and the
impact of lifestyle and environmental factors on CVD. Out-
come measures included blood pressure, lipoprotein proﬁle,
insulin resistance using the homeostasis model assessment
(HOMA), endothelial function using the brachial artery
reactivity test (BART), heart rate variability (HRV), medical
history, body mass index (BMI), hostility, depression, trait
anxiety, trait anger, stress, plasma cholesterol, triglycerides,
HDL cholesterol, plasma glucose, plasma insulin, and high-
sensitivity C-reactive protein (hs-CRP).
A signiﬁcant diﬀerence in adjusted systolic blood pres-
sure was observed at the end of the study in the tran-
scendental meditation group versus the health education
group (P = .04). No diﬀerences were found in lipoproteins,
hs-CRP, or BMI. There was a trend toward an increase
in physical activity in the health education group versus4 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
Table 1: Summary of clinical studies of mind-body therapies.
References
Design,
allocation
concealment∗
Modiﬁed
score
Mean age, sample
size (random-
ized/analyzed),
condition other
than metabolic
syndrome
Interventions
(regimen)
Main outcome
measures Main results Comments
Paul-Labrador
et al., 2006 [39]
Parallel
2 groups
Unmasked
5
Mean age = 67.4
Sample size = 103
Coronary heart
disease
Transcendental
meditation
versus health
education for
16 weeks
Blood pressure,
lipoprotein proﬁle,
insulin resistance
(HOMA),
endothelial
function (BART),
HRV, medication
history, BMI,
hostility,
depression, trait
anxiety, trait anger,
stress, plasma
cholesterol,
triglycerides,
HDL-C, plasma
glucose, plasma
insulin, and
hs-CRP
Signiﬁcant
diﬀerence in
systolic and
arterial blood
pressure at exit
No diﬀerence in
lipoproteins,
hs-CRP, BMI, or
BART Improved
glucose, insulin
levels, and HRV
in meditation
group
Trend toward
increase in
physical activity
in health
education group
Health
education group
more depressed
and angry at
entry and exit
Khatri et al.,
2007 [42]
Parallel
2 groups
Unknown
2
Mean age = 54.01
Sample size = 101
Usual care
versus usual
care plus yoga
for 12 weeks
BMI, waist
circumference,
blood pressure,
blood glucose,
HbA1c,
triglycerides,
HDL-C
Signiﬁcant
improvement in
waist
circumference,
blood pressure,
blood glucose,
HbA1c,
triglycerides, and
HDL-C in yoga
group
Cohen et al.,
2008 [43]
Parallel
2 groups
Unknown
3
Mean age = 52
Sample size = 24
Restorative
yoga versus
control
BMI, waist
circumference,
blood pressure,
insulin sensitivity,
plasma glucose,
plasma insulin,
triglycerides,
HDL-C, LDL-C,
demographics,
PSS, Block 2005,
physical activity,
SF-36, CES-D,
overall health
(Likert scale)
Trend toward
improved blood
pressure,
well-being, and
stress in yoga
group
Nonsigniﬁcant
changes in BMI
in yoga group
No diﬀerence in
serological
measures, diet,
or physical
activity
Yoga group
reported being
“very satisﬁed”
with
intervention,
felt that
practicing
restorative yoga
“very easy” or
“moderately
easy”
∗Classiﬁed by Cochrane criteria. HOMA: homeostasis model assessment; BART: brachial artery reactivity test; HRV: heart rate variability; BMI: body mass
index; HDL-C: high-density lipoprotein-cholesterol; hs-CRP: high-sensitivity C-reactive protein; HbA1c: hemoglobin A1c; LDL-C: low-density lipoprotein
cholesterol; PSS: Perceived Stress Scale; Block 2005: food frequency questionnaire; CES-D: Center for Epidemiologic Study-Depression Scale; PSQ:P e r c e i v e d
Stress Questionnaire; SF-36 (measures physical and mental aspects of health).
the transcendental meditation group. The health education
group was more depressed and angry at the beginning
and end of the study period than was the transcendental
meditation group. Improved plasma glucose and insulin
levels were observed in the transcendental meditation group
versus the health education group at the conclusion of the
study period (P = .01). No diﬀerence in endothelial function
was observed. A signiﬁcant diﬀerence in the change in the
high-frequency HRV was observed in the transcendental
meditation group versus the health education group at theJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 5
end of the study after adjusting for covariates (P = .02), with
a trend toward a change in the measurements of total power
and low-frequency HRV (P = .07).
Khatriandcolleagues[42](modiﬁedscore=2)evaluated
the eﬃcacy of a yoga intervention plus usual care versus
usual care alone in individuals (N = 101) with the metabolic
syndromeinarandomizedstudyoverthecourseof12weeks.
Outcome measures included BMI, waist circumference,
blood pressure, blood glucose, glycosylated hemoglobin
(HbA1c), triglycerides, and HDL. Signiﬁcant improvements
in waist circumference, systolic and diastolic blood pressure,
blood glucose, HbA1c, triglycerides, and HDL (P<. 001)
were observed in the yoga group from baseline to the end
of the study period. A comparison to the control group was
not given.
Cohen and colleagues [43] (modiﬁed score = 3) exam-
ined the eﬀects of a restorative yoga intervention using
a parallel study design. The yoga intervention consisted
of a 3-hour introduction class, followed by a 90-minute
class two times per week for 5 weeks, and then one class
weekly for 5 weeks. Subjects (n = 24) randomized to
the yoga group were to practice 3 times per week outside
of class, tracking activity in a log book. The control
group received no intervention. Outcome measures included
BMI, waist circumference, blood pressure, insulin sensitivity,
plasma glucose, plasma insulin, triglycerides, HDL, LDL,
demographic information, perceived stress (PSS), dietary
information using a food frequency questionnaire (2005
Block questionnaire), physical activity, quality of life (SF-
36), depression (CES-D), and a self-rating of overall health
using a Likert scale. Trends toward improved blood pressure
(P = .07), well-being (P<. 12), and stress (P<. 22) were
observed, as well as nonsigniﬁcant changes in weight and
B M Ii nt h ey o g ag r o u p .T h e r ew a sn od i ﬀerence in any of
the serological measures in either group at the end of the
study. The yoga group reported a signiﬁcant improvement
in energy level (P<. 009). No signiﬁcant changes in
diet or physical activity were reported. The yoga group
reported being “very satisﬁed” with the intervention, with
the majority (87%) ﬁnding the practice of restorative yoga
“very easy” or “moderately easy.” This study demonstrates
the feasibility of recruiting overweight individuals with the
metabolic syndrome for a yoga study.
4. Discussion
A very small number of clinical trials addressing the use
of mind-body therapies for management of the metabolic
syndrome were identiﬁed in the process of conducting this
review. Though the studies support the potential clinical
eﬀectiveness of mind-body practices in improving indices of
themetabolicsyndrome,morestudiesarerequiredgiventhat
the trials included had several limitations. In the study by
Paul-Labrador and colleagues [39] ,al a c ko fad e s c r i p t i o no f
the psychosocial outcome measures used as well as baseline
diﬀerences in depression and anger make the results diﬃcult
to interpret. Moreover, a usual care alone group was not
included in the study, which is essential when making
comparisons to the standard of care. The use of HOMA as
a measure of insulin resistance is an indirect method that
may have underestimated eﬀects of the interventions in the
reviewed studies. None of the studies indicated the use of
ambulatorybloodpressuremonitoringoverthecourseofthe
study. Measurement of blood pressure only at study intervals
might have underestimated the eﬃcacy of the mind-body
interventions in lowering this key component/symptom of
the metabolic syndrome. Only one of the reviewed studies
did not include waist circumference as an outcome measure
[39]. The study by Khatri and colleagues [42] was published
as a brief correspondence, limiting the description of the
study population, the methods, the intervention, and the
results, including a comparison of the intervention with the
controlgroup.Norationalewasgivenfortheinconsistencyin
the duration and timing of the intervention over the course
of the study period in the trial by Cohen and colleagues [43].
Additionally,thislatterstudyhadasmallsamplesizelimiting
the statistical power of the results, a brief follow-up period
thatmayhavediminished theestimationofeﬀects,andthose
participants in the yoga group may have been aﬀected by the
group dynamics of the yoga classes.
For the results of a clinical study to be useful, one must
be able to replicate the trial; therefore, all aspects of the
methodology and the intervention, as well as a detailed
description of the results, must be reported. None of the
included studies in this paper provided a clear rationale for
the treatment speciﬁcity or duration. Given that the optimal
dosage of mind-body therapies has yet to be determined,
a description of the treatment duration and number of
treatments should be included. While there remains a lack of
rigorous trials that apply adequate methodology, including
the use of blinding and placebo treatments, given that
trials with inadequate levels of blinding are likely to show
exaggerated treatment eﬀects [47], the nature of mind-body
therapies makes it seemingly impossible to blind subjects to
the intervention or to develop a placebo.
Given the physiological outcomes associated with the
metabolic syndrome, objective outcome measures such as
lipoprotein proﬁles, circulating levels of glucose and insulin,
and anthropometric measures are consistent across studies
of the metabolic syndrome, which allows for comparison
among studies. However, diﬀerent subjective assessments
were used in the included studies to determine subjective
or psychosocial outcomes such as fatigue and health-related
quality of life, making comparisons more challenging. This
issue is not unique to the study of mind-body or comple-
mentary therapies. Indeed, RCTs often use various outcome
measuresofpatientsymptomstoquantifythesameconcepts,
limiting comparison across studies [48]. Additionally, some
patient-reported outcomes are likely not to be captured
because of a lack of sensitivity of the instrument or to the
ﬂoor and ceiling eﬀects of some measures that do not assess
symptom extremes adequately [48], a potential limitation
acknowledged by Paul-Labrador and colleagues [39]. The
Patient-Reported Outcomes Measurement Information Sys-
tem (PROMIS) Initiative aims to improve appreciably how
these measures are selected and assessed in clinical research,
including clinical trials [48]. As part of the NIH Roadmap
Initiative, use of these measures supports the goals of the6 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
PROMIS Initiative to revolutionize the way patient-reported
outcome tools are used in clinical research and practice
and to aid in transforming the nation’s medical research
capabilities, speeding the movement of research [49].
Limitations of systematic reviews, including the current
paper, relate to any potential incompleteness of the reviewed
studies. This eﬀect may result from publication bias given
that negative studies tend to remain unpublished [50]. A
furtherweaknessofthecurrentpaperinvolvesthelimitations
of the reviewed studies. Methodological shortcomings such
as small sample size and inadequate reporting of methods
andresultsleavetheoverallresultinconclusive.Theexclusion
of studies focusing on clinical outcomes related to single
components of the metabolic syndrome may be a limitation;
however, the inclusion of trials examining only certain
cardiometabolic measures would not provide reliable data
on the clinical eﬀectiveness of mind-body therapies in
improvingthesymptomclusterthatcomprisesthemetabolic
syndrome as a whole.
Mind-body therapies may carry practical advantages as
therapeutic interventions for managing the symptom cluster
associated with the metabolic syndrome. While several
large trials have demonstrated the eﬀectiveness of physical
activity in improving outcomes of the metabolic syndrome,
many individuals, such as those who are overweight and
sedentary and at highest risk for the metabolic syndrome,
may be unable or unwilling to participate in conventional
types of physical activity (e.g., strength training and gym-
based exercises) [41, 43]. Mind-body modalities are simple,
economical, noninvasive therapies, easy to learn, and can be
practiced easily by individuals who may experience potential
limitations in mobility [51]. Requiring little in the way of
equipment or professional personnel, mind-body therapies
are relatively easy and inexpensive to practice. Moreover,
mind-body therapies typically bring immediate positive
beneﬁts, including feelings of relaxation and tranquility. For
example, even short-term qigong programs (20 days to 10
weeks) have been shown to result in signiﬁcant improve-
ments in sleep, mood, and other distressful symptoms, as
well as cardiovascular health [35, 52], helping to encourage
continued practice. Several studies indicate that qigong and
other mind-body programs may reduce healthcare costs in
both clinical and nonclinical populations [53, 54].
5. Conclusion
Clearly, there is a need to identify cost-eﬀective prevention
and management strategies for the metabolic syndrome
that address the multiple interrelated factors underlying
this complex, devastating, and rapidly increasing chronic
condition. No such research has been conducted in this
regard with respect to mind-body therapies. Current clinical
practice guidelines indicate lifestyle modiﬁcations as the sole
therapy for prehypertension, as well as other indicators of
the metabolic syndrome [55]. Given the positive eﬀects of
mind-body therapies on cardiometabolic components, these
modalities most likely would be of beneﬁt to individuals
with the metabolic syndrome. The current paper provides
healthcare practitioners with information that could be
used in decision-making about recommendations involving
mind-body practices. In light of the important role of
psychosocial factors in the development of insulin resistance,
type 2 diabetes, and other chronic diseases, the inﬂuence
of sympathetic activation in the pathogenesis of insulin
resistant states and the bidirectional relationships of these
and other insulin resistance-related risk factors and mind-
body therapies may hold promise for both the prevention
and treatment of the metabolic syndrome. Because RCTs
remainthe“goldstandard”inbiomedicalresearch,thispaper
highlights the need for such trials of mind-body therapies
with regard to the management of the metabolic syndrome,
given the relative absence of such studies in the literature,
as well as the mechanisms of action involved in mind-body
therapies.
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